Sio Gene Therapies Inc.: insider trades · United States · SEC (Form 4)

About Sio Gene Therapies Inc.

Sio Gene Therapies Inc. was a U.S. biopharmaceutical company focused on gene therapy, historically aimed at severe neurodegenerative disorders and other rare pediatric monogenic diseases. The company was originally incorporated in October 2014 as Axovant Gene Therapies Ltd., then underwent a major corporate transformation in November 2020, including a change of domicile to Delaware and a rebrand to Sio Gene Therapies Inc. It traded on the NASDAQ Global Select Market under the ticker SIOX. The company was headquartered in the United States, in New York, and its public-market context was the U.S. NASDAQ, placing it in the high-risk, high-volatility small-cap biotech segment. Operationally, Sio was a clinical-stage development company with no meaningful commercial product revenue. Its strategy centered on adeno-associated virus (AAV) gene therapy candidates for devastating neurological conditions, particularly GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs/Sandhoff disease). Key programs included AXO-AAV-GM1 and AXO-AAV-GM2, with a therapeutic thesis built around potentially disease-modifying or curative genetic correction. In competitive terms, Sio operated in a crowded but scientifically compelling rare-disease gene therapy field, where differentiation depends on clinical efficacy, safety, manufacturing execution, and the ability to secure continued funding. The company’s recent history is dominated by strategic retrenchment and wind-down. In 2022, Sio announced a plan of complete liquidation and dissolution. Nasdaq later announced that it would delist the common stock in April 2023 after the shares were suspended for non-compliance with the minimum bid price requirement. Stockholders approved the dissolution, and the liquidation of foreign subsidiaries was completed in January 2024. A February 2024 announcement indicated that Sio intended to file a certificate of dissolution in Delaware and make an initial liquidating distribution. For investors, the current relevance of Sio is therefore primarily historical and corporate-action driven rather than operating-performance driven: it is an example of a U.S.-listed gene therapy developer that moved from a R&D-heavy pipeline story to an orderly liquidation process, with the investment case ultimately shaped by delisting, dissolution, and residual asset distribution rather than ongoing drug development.